What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5 — a partially purified calf thymus extract. It is the N-terminally acetylated form of a peptide derived from the prothymosin alpha precursor protein and is produced naturally by thymic epithelial cells. Thymosin Alpha-1 has been studied extensively in immunological research and has investigational and approved uses in select jurisdictions outside Canada and the United States, primarily in the context of certain chronic viral infections and as an immunological adjuvant in experimental oncology settings.

As a research compound in Canada, Thymosin Alpha-1 is supplied by TrueCanPeptides for qualified laboratory and preclinical investigational use. It is not approved by Health Canada for therapeutic use.

Mechanism of Action — Research Context

In preclinical and early-phase research, Thymosin Alpha-1 has been studied for its interactions with innate and adaptive immune system pathways. It is thought to act partly through Toll-like receptor (TLR) signalling, particularly TLR2 and TLR9, which are pattern recognition receptors involved in innate immune activation. Research has also examined Tα1 in relation to T-cell maturation, dendritic cell function, and cytokine modulation in controlled experimental settings.

The compound has a well-characterised safety profile in the research literature relative to many immunological peptides, which contributes to its use as a tool compound in immune biology experiments. All mechanistic references here derive from preclinical and investigational literature.

Research Applications

• Immune biology research: Thymosin Alpha-1 is widely studied as a modulator of T-cell and dendritic cell function in controlled immunology experiments.
• TLR signalling studies: Researchers use Tα1 to investigate Toll-like receptor pathway activation and innate immune responses in in vitro and animal models.
• Infectious disease models: Preclinical investigations have studied Thymosin Alpha-1 in viral and bacterial infection models, examining immune response modulation.
• Oncology research (experimental): Early research has examined Tα1 in combination protocols within experimental tumour immunology models.
• Vaccine adjuvant research: Thymosin Alpha-1 has been investigated as a potential adjuvant component in experimental vaccine models, studied for its ability to enhance antigen-specific immune responses.

View Thymosin Alpha-1 5mg — Research Grade

Storage & Handling

Thymosin Alpha-1 should be stored and handled using standard research-grade peptide protocols:

• Store lyophilised peptide at −20°C in sealed containers, protected from moisture and light
• Reconstitute using sterile bacteriostatic water or appropriate buffer according to your research protocol
• Reconstituted solution should be refrigerated at 4°C and used within the timeframe specified by your laboratory SOP
• Do not expose to repeated freeze-thaw cycles; aliquot as needed for multi-use experiments

For more detail, consult our Peptide Storage Guide. Purity and certificate of analysis information is provided on our Quality & Purity page.

Related Research

Thymosin Alpha-1 belongs to the thymosin family of immunologically active peptides, which includes thymosin Beta-4 and thymalin. Researchers investigating immune-modulation themes may also review literature on LL-37, a host defence peptide with overlapping immune biology themes, and general antimicrobial peptide research. For immune-endocrine interface research, Thymosin Alpha-1 is sometimes studied alongside thymic hormones and neuropeptides.

Browse the Research Hub for additional compound overviews or read What Are Peptides? for foundational context.

⚠️ Research Use Only: All content on this page is intended strictly for educational and informational purposes. This compound is not approved by Health Canada or any regulatory agency for human therapeutic use. TrueCanPeptides supplies research-grade compounds to qualified researchers only. This is not medical advice. Do not use any information here for self-administration, diagnosis, or treatment. Consult a licensed healthcare professional for any medical concerns.

See also: What is LL-37?

Discovery and Origin

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5 — a bovine thymus extract — by Allan Goldstein at the George Washington University in the 1970s. It was identified as the primary biologically active component of the thymosin fraction responsible for T-cell maturation activity. Unlike Thymalin (a broader polypeptide complex from similar thymic origins), Thymosin Alpha-1 has a fully defined single sequence, making it a more precise pharmacological research tool.

Structure and Chemistry

• Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (28 AA, N-terminal acetylation)
• Amino acids: 28
• Molecular weight: ~3,108 Da
• N-terminal modification: Acetylation (required for biological activity; non-acetylated form is inactive)
• Format: Lyophilized powder
• Commercial INN: Thymalfasin (approved in some countries as Zadaxin)

Mechanisms in Immune Research

Thymosin Alpha-1 has been studied for the following mechanisms in immune cell models:

• T-cell maturation: Promotes differentiation of immature thymocytes into mature CD4+ and CD8+ T-cell populations in thymic culture models
• Dendritic cell activation: Studied for its effects on plasmacytoid dendritic cell (pDC) and conventional DC maturation and type I interferon production
• TLR signalling: Research has associated Tα1 with enhanced toll-like receptor (TLR7/TLR9) signalling in pDCs, supporting interferon-alpha production in models of innate immune activation
• Th1 cytokine bias: In T-cell co-culture models, Tα1 has been associated with promotion of Th1 (interferon-gamma, IL-2) vs Th2 cytokine profiles

Clinical Research Context

Thymosin Alpha-1 has reached clinical use in some countries under the brand name Zadaxin (SciClone Pharmaceuticals) — approved in certain markets for hepatitis B, hepatitis C adjunct therapy, and as an immune-modulating agent in some oncology contexts. This makes Tα1 one of the few thymic peptides with documented clinical pharmacology data, though it is not approved in Canada or the US for any indication. The clinical development history provides a richer mechanistic research foundation than most peptides in this category.

Storage and Handling

• Store lyophilized at −20°C; −80°C for long-term storage
• Reconstitute in sterile water; water-soluble at physiological pH
• The N-terminal acetylation is stable — no special handling required beyond standard peptide precautions
• Post-reconstitution: aliquot and store at −80°C; minimize freeze-thaw cycles

Thymosin Alpha-1 is supplied for qualified in vitro laboratory research purposes only. Not for human or animal administration. Not evaluated or approved by Health Canada.

Available: Thymosin Alpha-1 5mg from TrueCanPeptides | Thymalin 10mg | Immune & Longevity research compounds